The Scripps Research Institute

Ortho Diagnostic Systems Inc.

Merck Sharp + Dohme Corp.

Georgetown University

Johnson & Johnson Gmbh

Ortho-clinical Diagnostics, Inc

Myelos Corporation

D Elliot Parks

Richard A Lerner

Richard S Smith

Joakim Dillner

Gary R Pearson

Susan Pothen Varghese

Andrew J Bett

Beth-Ann Griswold Coller

Vidya B Pai, Jr

Michele Yelmene

Timothy Martyak

David Erick Wright

Erling C Norrby

The present invention provides dengue virus vaccines and immunogenic compositions for administration to human subjects. The vaccine compositions of the present invention comprise recombinantly produced monomeric and/or dimeric forms of truncated dengue virus envelope glycoprotein that, when formulated together with an adjuvant and a pharmaceutically acceptable carrier, induce balanced tetravalent immune responses. In preferred embodiments of the compositions described herein, the DEN4 protein component is a dimeric form of DEN4. The compositions are designed to be acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. Also provided herein are methods of inducing a protective immune response in a human patient population by administering the compositions described herein to the patients.

Recombinant subunit dengue virus vaccine

This invention provides methods of treatment using retro-inverso peptides derived from interleukin-6 (IL-6) having between 15 and about 40 amino acids, and including the sequence that is retro-inverso with respect to SEQ ID NO: 1, i.e. wherein said peptide comprises the sequence D-Glu-D-Ala-D-Met-D-Lys-D-Pro-D-Leu-D-Asn-D-Leu-D-Asn-D-Asn-D-Glu-D-Ala-D-Leu-D-Ala-D-Glu. The peptides of the invention have the same activity as native IL-6 and also have neurotrophic activity. The peptides of the invention are also less susceptible to proteolytic degradation in vivo because of their D-amino acid linkage.

Retro-inverso peptides derived from interleukin-6

The Epstein-Barr virus (EBV) specific polypeptides ETFTETWNRFITHTE (SEQ. ID NO: 1), GMLEASEGLDGWIHQ (SEQ. ID NO:2), HQQGGWSTLIEDNIP (SEQ. ID NO:3), and KQKHPKKVKQAFNPL (SEQ. ID NO:4) are among those disclosed. Also disclosed are the use of these polypeptides for the production of polypeptide-specific antibodies and the diagnosis and treatment of EBV-associated disease.

Immunoreactive peptides from Epstein-Barr virus

Epstein-Barr virus (EBV) specific polypeptides are disclosed. Also disclosed are the use of these polypeptides for the production of polypeptide-specific antibodies and the diagnosis and treatment of EBV-associated disease.

Epstein-Barr virus (EBV) specific polypeptides consisting of a series of one to 1000 peptide units selected from the group consisting of peptide units &#x3a6;, &#x393;, &#x394; and &#x3a9;, wherein &#x3a6; is 25 amino acids or less and has the formula (&#x3b1;ETFTETWNRFITHTE&#x3b2;) (SEQ ID NO:1), &#x393; is 25 amino acids or less and has the formula (&#x3b1;GMLEASEGLDGWIHQ&#x3b2;) (SEQ ID NO:2), &#x394; is 25 amino acids or less and has the formula (&#x3b1;HQQGGWSTLIEDNI&#x3b2;) (SEQ ID NO:3), &#x3a9; is 25 amino acids or less and has the formula (&#x3b1;KQKHPKKVKQAFNPL&#x3b2;) (SEQ ID NO:4), &#x3b1; and &#x3b2; are each independently from 0 to 5 naturally occurring amino acids, and the polypeptide is capable of binding antibody in a specimen from an individual with Epstein-Barr virus (EBV)-associated disease are disclosed. Also disclosed are the use of these polypeptides for the production of polypeptide-specific antibodies and the diagnosis and treatment of EBV-associated disease.

A novel assay utilizing Epstein-Barr virus (EBV) specific peptides is disclosed. The assay is particularly useful for detecting early antigen antibodies in a blood sample from an individual having an EBV-associated disease, the disease preferably being infectious mononucleosis.

Method for diagnosis of Epstein-Barr virus associated disease

The simian immunodeficiency virus (SIV) is genotypically and phenotypically similar to the human immunodeficiency virus type 2 (HIV-2). Both viruses display similar structural, biological, and immunological properties. The external envelope glycoprotein (EMP) and transmembrane envelope glycoprotein (TMP) appear to be formed from the cleavage of a precursor glycoprotein. Despite these similarities, a number of differences exist as evidenced by the different migratory properties of the envelope glycoproteins. The present invention discloses novel SIV peptides, obtained from the transmembrane envelope glycoprotein, that display immunological cross-reactivity with HIV-2-specific antisera. Epitope mapping studies revealed that the amino acid sequence --CAFRQVC--, which corresponds to amino acid residues 614-620, is a sine qua non for the retention of this immunological cross-reactivity. These peptides are useful in diagnostic methods for the detection of HIV-2-specific antibodies in infected patients.

Methods and diagnostic kits for the detections of HIV-2-specific

The present invention relates to polypeptides that immunologically mimic papillomavirus latent proteins and to antibodies and monoclonal antibodies that immunoreact with papillomavirus latent proteins. Systems and methods for detecting the presence and type of papillomavirus in a human subject are also described.

Growing community of inventors

Del Mar, CA, United States of America

D Elliot Parks